SYMBICORT® in the Treatment of COPD (SRP COPD)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00564499
First received: November 26, 2007
Last updated: January 27, 2011
Last verified: January 2011

November 26, 2007
January 27, 2011
March 2006
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00564499 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
SYMBICORT® in the Treatment of COPD
A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Not Provided
Observational
Observational Model: Case-Crossover
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients

COPD
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
May 2007
Not Provided

Inclusion Criteria:

  • patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

  • patients who recently quit smoking (<3months)
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00564499
SRP-RB-COPD-2005/1
No
Not Provided
AstraZeneca
Not Provided
Principal Investigator: E Louis, PR Université Libre de Liège
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP